Dr. Emily Day is Associate Professor in the Department of Biomedical Engineering at the University of Delaware, where she began her faculty career in 2013. She obtained her B.S. in Physics with a Minor in Mathematics from the University of Oklahoma in 2006, graduating summa cum laude. Subsequently, she received her Ph.D. in Bioengineering from Rice University under the guidance of Dr. Jennifer West. There, she developed nanoparticle-mediated photothermal therapy to treat glioblastoma, a lethal form of brain tumor. During her time at Rice University, Dr. Day received a National Science Foundation Graduate Research Fellowship, a Rice President’s Graduate Fellowship, and was also named a Howard Hughes Medical Institute Med-Into-Grad Fellow. Upon completing her Ph.D. in 2011, Dr. Day joined the laboratory of Dr. Chad Mirkin at Northwestern University, where she developed RNA-gold nanoparticle conjugates to treat glioblastoma through gene regulation. Dr. Day received an International Institute for Nanotechnology postdoctoral fellowship and a National Institutes of Health F32 Ruth L. Kirschstein National Research Service Award during her time at Northwestern University. Her current research builds upon the theme of engineering nanoparticles for high precision therapy of disease developed during her graduate and postdoctoral work. She has received several notable grants and awards for her independent research, including the 2018 Rita Schaffer Award from the Biomedical Engineering Society, an NSF CAREER Award, the 2018 Young Innovator in Cellular and Molecular Bioengineering (CMBE) Award from CMBE Journal, the 2018 Young Innovator in Nanobiotechnology Award from Nano Research Journal, the 2018 Gerard J. Mangone Young Scholar Award from the University of Delaware Francis Alison Society, an NIH R35 Grant, an NIH R01 Grant, and a W.M. Keck Foundation Science and Engineering Grant. Additionally, she was a selected participant in the 2019 National Academy of Engineering Frontiers of Engineering Symposium.